Syndax Pharmaceuticals Competitors and Similar CompaniesClear all

Syndax Pharmaceuticals's competitors and similar companies include TSH Biopharm, United Biopharma, Epizyme and X4 Pharmaceuticals.

	Syndax Pharmaceuticals Syndax Pharmaceuticals is a late-stage clinical development oncology company focused on overcoming the problem of resistance in cancer therapy.	TSH Biopharm TSH Biopharm (東生華製藥股份有限公司) is a pharmaceutical company focused on chronic diseases.	United Biopharma United BioPharma is a company dedicated to the development and commercialization of monoclonal antibodies.	Epizyme Epizyme is a clinical stage biopharmaceutical company focusing on treatments for blood cancer and tumors.	X4 Pharmaceuticals X4 Pharmaceuticals (formerly known as Arsanis) is a biopharmaceutical company that provides drug development services.
Founding Date	Founding Date 2005	Founding Date 2010	Founding Date 2013	Founding Date 2007	Founding Date 2010
Type	Type Public	Type Public	Type Private	Type Public	Type Public
Tags	Tags Healthcare biotech oncology pharma	Tags Healthcare biotech oncology pharma	Tags Healthcare biotech oncology pharma	Tags Healthcare biotech oncology pharma	Tags Healthcare biotech drug development pharma therapy
Locations	Locations Waltham, US HQ New York, US Waltham, US	Locations TW HQ	Locations TW HQ Yangzhou Shi, CN Hauppauge, US	Locations Cambridge, US HQ	Locations Boston, US HQ Wien, AT
Employees	Employees 358% decrease	Employees 76	Employees 393% decrease	Employees 20364% increase	Employees 1005% increase
Valuation ($)	Valuation ($) 1.6 b	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) 250.8 m	Valuation ($) 83.9 m
Financial
Revenue (est.)	Revenue (est.) $172.4m (FY, 2025)	Revenue (est.) NT$1.3b (FY, 2025)	Revenue (est.) N/A	Revenue (est.) $37.4m (FY, 2021)	Revenue (est.) $6.5m (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods NT$629m (FY, 2025)	Cost of goods N/A	Cost of goods $10.5m (FY, 2021)	Cost of goods $5.8m (FY, 2025)
Gross profit	Gross profit N/A	Gross profit NT$709.7m (FY, 2025)	Gross profit N/A	Gross profit N/A	Gross profit $743k (FY, 2025)
Net income	Net income ($285.4m) (FY, 2025)	Net income NT$187.8m (FY, 2025)	Net income N/A	Net income ($251.1m) (FY, 2021)	Net income N/A
Funding
Total funding raised	Total funding raised N/A	Total funding raised N/A	Total funding raised N/A	Total funding raised $ 51.5m	Total funding raised $ 64.5m